Ubrelvy Does Not Contain NSAID or Aspirin Components
Ubrelvy (ubrogepant) is a pure CGRP receptor antagonist with no NSAID or aspirin component in its formulation. 1
Active and Inactive Ingredients
The only active ingredient in Ubrelvy is ubrogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. 1
The inactive ingredients are colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, polyvinylpyrrolidone vinyl acetate copolymer, sodium chloride, sodium stearyl fumarate, and vitamin E polyethylene glycol succinate—none of which are NSAIDs or aspirin. 1
Mechanism of Action
Ubrogepant works by blocking CGRP receptors, which are key mediators of migraine pain, rather than through anti-inflammatory pathways used by NSAIDs or aspirin. 2, 3
CGRP levels are significantly elevated during migraine attacks, and ubrogepant's receptor antagonism provides pain relief without the cardiovascular risks or gastrointestinal effects associated with NSAIDs. 2, 3
Clinical Use and Combination Therapy
Ubrogepant is recommended as a second-line agent for patients who fail or cannot tolerate triptan plus NSAID combination therapy. 4, 5
The FDA label explicitly documents that no significant pharmacokinetic interactions occur when Ubrelvy is co-administered with acetaminophen, naproxen, or sumatriptan, confirming these agents can be safely combined if clinically indicated. 1
Ubrogepant offers an effective alternative for patients with contraindications to NSAIDs (such as peptic ulcer disease, renal impairment, or cardiovascular disease) or triptans (such as coronary artery disease or uncontrolled hypertension). 2, 6